Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

Part of paid clinical trials in Norwich, Connecticut.

Sponsor
New England Retina Associates
Study ID
NCT01253694
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Treatment with Ranibizumab of the residual diabetic edema in patients with failed response to Bevacizumab.

Key Dates

First listed
Dec 3, 2010
Start date
Mar 31, 2011
Status verified
May 2013
Primary completion
Jun 30, 2012
Completion
Jul 31, 2012

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with 3-5 consecutive Avastin injections
    These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
  • Experimental: Patients with 6 or more consecutive injections of Bevacizumab
    Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.

Primary Outcome Measure

Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns. [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
New England Retina AssociatesNorwichConnecticut06360-

Find similar trials in Norwich, CT

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
New England Retina Associates· Norwich, CT

Related Studies